Goldenwell Biotech annual operating margin
2021
2022
2023
2024
2025
Goldenwell Biotech's operating margin was −206,047.27% for fiscal 2025.
View full Goldenwell Biotech company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −206,047.27% | −117487.56 pp |
| 2024 | 2024-12-31 | −88,559.71% | −83609.88 pp |
| 2023 | 2023-12-31 | −4,949.83% | −2888.94 pp |
| 2022 | 2022-12-31 | −2,060.89% | −1320.19 pp |
| 2021 | 2021-12-31 | −740.70% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | −41,627.27% | −32358.69 pp |
| Q2 2024 | 2024-06-30 | −34,402.88% | −24589.83 pp |
| Q1 2024 | 2024-03-31 | −18,326.58% | −15963.29 pp |
| Q4 2023 | 2023-12-31 | −7,588.46% | −7577.97 pp |
| Q3 2023 | 2023-09-30 | −9,268.59% | −8546.80 pp |
| Q2 2023 | 2023-06-30 | −9,813.04% | −1403.22 pp |
| Q1 2023 | 2023-03-31 | −2,363.29% | −1634.10 pp |
| Q3 2022 | 2022-09-30 | −10.49% | — |
| Q2 2022 | 2022-06-30 | −721.79% | — |
| Q1 2022 | 2022-03-31 | −8,409.82% | — |
| Q3 2021 | 2021-09-30 | −729.19% | — |
Across the available reported history, Goldenwell Biotech's operating margin decreased from −88,559.71% to −206,047.27%, a change of −117487.56 percentage points. The latest reported quarter, Q4 2025, shows −41,627.27%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Goldenwell Biotech filings at SEC.gov ↗